Last update Dec. 24, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 30 | % |
Molecular weight | 333 | daltons |
Protein Binding | > 95 | % |
VD | 1 | l/Kg |
pKa | 9.74 | - |
Tmax | 1 | hours |
T½ | 16 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a nucleoside analogue effective in vitro against herpes simplex virus type 1 and varicella-zoster virus. Used in treatment of Herpes zoster and herpes simplex. Oral and topical administration.
At latest update, relevant published data on excretion into breast milk were not found.
Because a high distribution volume (DV) and high protein-binding capacity, excretion into breast milk in significant amount is very unlikely.
Its low oral bioavailability impairs the pass of it from the mother's milk to the infant's plasma, except in prematures or in the early neonatal period, when a higher intestinal absorption may occur.
Until more data on this medication is available, safer alternative drugs are preferred, especially in such critical age periods.
See below the information of these related products: